Mark Lebwohl, MD: Implications of 4 Year Data on Bimekizumab for Psoriasis Treatment hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.
Both an approved anti-IL-17 therapy and an experimental oral anti-IL-23 therapy appeared to achieve relatively undiminished rates of psoriasis control in extension studies.
There are many drugs that have been around for years and others with strong data awaiting FDA approval that are beneficial in treating conditions like atopic dermatitis and alopecia areata, said James Q. Del Rosso, DO.
Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.